IHT Wealth Management LLC trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 1.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,799 shares of the company’s stock after selling 133 shares during the quarter. IHT Wealth Management LLC’s holdings in Eli Lilly And Co were worth $1,551,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Pacitti Group Inc. bought a new stake in shares of Eli Lilly And Co in the 4th quarter worth approximately $25,000. Sugarloaf Wealth Management LLC purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $26,000. Solstein Capital LLC purchased a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $34,000. Capital Wealth Alliance LLC bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $34,000. Finally, Retirement Network bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at approximately $38,000. Institutional investors own 77.83% of the company’s stock.

LLY has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $156.00 price target on shares of Eli Lilly And Co in a report on Tuesday, February 18th. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price for the company in a research report on Wednesday, March 11th. Mizuho began coverage on shares of Eli Lilly And Co in a research note on Wednesday, February 5th. They set a “neutral” rating and a $148.00 target price on the stock. Morgan Stanley upgraded shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $116.00 to $150.00 in a research report on Wednesday, December 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. increased their price target on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $142.18.

LLY stock opened at $121.94 on Thursday. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $147.87. The business’s 50 day moving average price is $137.27 and its two-hundred day moving average price is $124.78. The company has a debt-to-equity ratio of 5.30, a quick ratio of 0.89 and a current ratio of 1.16. The company has a market capitalization of $117.61 billion, a price-to-earnings ratio of 13.92, a price-to-earnings-growth ratio of 1.54 and a beta of 0.34.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Thursday, January 30th. The company reported $1.73 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.21. Eli Lilly And Co had a return on equity of 192.27% and a net margin of 37.27%. The firm had revenue of $6.11 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the business earned $1.33 EPS. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly And Co will post 6.77 earnings per share for the current year.

In other Eli Lilly And Co news, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total transaction of $3,503,750.00. Following the completion of the sale, the senior vice president now directly owns 44,773 shares in the company, valued at approximately $6,274,935.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $135.79, for a total transaction of $29,873,800.00. Following the sale, the insider now owns 114,136,224 shares of the company’s stock, valued at $15,498,557,856.96. The disclosure for this sale can be found here. Insiders have sold 682,645 shares of company stock valued at $95,516,671 in the last quarter. 0.11% of the stock is owned by company insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Why are trading ranges significant?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.